Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536846 · ClinicalTrials.gov registry record · Phase 4
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
A Phase 4 study of Healthy, sponsored by Dost Ongur.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT02536846: Completed Phase 4 study of Healthy, sponsored by Dost Ongur.
NCT02536846 is a Phase 4 study of Healthy that has completed, run by Dost Ongur. The registered enrollment target is 35 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02536846, a Phase 4 study of Healthy, has completed, sponsored by Dost Ongur.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to investigate antipsychotic drug effects on healthy brain metabolism.
Conditions Studied
Interventions
- DRUG Olanzapine
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-11-17 |
| Est. Completion | 2019-11-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02536846
The ClinicalTrials.gov registry entry for NCT02536846 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is Dost Ongur, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Olanzapine is the first listed.
NCT02536846 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02536846 about?
NCT02536846 is a clinical study titled "The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals". The primary aim of this study is to investigate antipsychotic drug effects on healthy brain metabolism.
What is the current status of trial NCT02536846?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2017-11-17. Estimated completion is 2019-11-08.
What conditions does trial NCT02536846 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02536846?
The interventions under investigation include: Olanzapine (DRUG).
Who is sponsoring clinical trial NCT02536846?
This trial is sponsored by Dost Ongur, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02536846 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
-
Pharmacokinetics of Transdermal Metronidazole
ACTIVE NOT RECRUITING · Phase 4
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.